Clinical trials
Locally Advanced (Unresectable) or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced (unresectable) or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 2,084 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05683886RecruitingPhase 2
Study KC1036 for advanced thymus tumors after chemotherapy
This trial tests KC1036 in people with advanced thymoma or thymic carcinoma whose cancer came back or spread after their first standard chemotherapy. It may offer a new treatment option when earlier treatment no longer worked.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Birmingham, AlabamaAges 18 years+ - NCT05985954RecruitingPhase 1
Ulixertinib with cetuximab for colorectal cancer
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
Houston, TexasAges 18 years+ - NCT06078787RecruitingPhase 2
Olaparib for advanced pancreatic cancer with PALB2 mutation
This trial tests whether the drug olaparib can help people with advanced pancreatic cancer that has a specific change in the PALB2 gene. You may qualify if your cancer has spread or cannot be removed with surgery and you have already tried at least one other treatment.
ModenaAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06208657RecruitingPhase 1/Phase 2
Personalized cancer therapy for kids and teens
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
Newcastle, New South WalesAges birth–21 years - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06277154RecruitingPhase 2
MASCT-I plus chemo for first-line advanced soft tissue sarcoma
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
GuangzhouAges 18–70 - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Birmingham, AlabamaAges 18 years+ - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT06502691RecruitingPhase 1/Phase 2
New imaging test to measure PARP in metastatic breast cancer
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Seattle, WashingtonAges 18 years+ - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06731270RecruitingPhase 2
Diclofenac for advanced lung cancer on immunotherapy
This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.
Atlanta, GeorgiaAges 18 years+ - NCT06897644RecruitingPhase 3
Comparing two chemotherapy strategies for advanced pancreatic cancer
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Aviano, ItalyAges 18 years+ - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07067385RecruitingPhase 1
Personalized mRNA vaccine for advanced GI cancers
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
Shanghai, SHAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years - NCT03138161RecruitingPhase 1/Phase 2
Testing three medicines for previously treated soft-tissue sarcoma
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
Santa Monica, CaliforniaAges 18 years+
Hear when a new Locally Advanced (Unresectable) or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced (unresectable) or metastatic solid tumors?
- Yes. Clin2 currently lists 2,084 recruiting locally advanced (unresectable) or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced (unresectable) or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced (unresectable) or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.